Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bioxyne Limited ( (AU:BXN) ) just unveiled an update.
Bioxyne Limited has applied for quotation on the ASX of 1,825,000 ordinary fully paid shares, to be issued on 17 March 2026 under its existing ticker BXN. The new securities arise from the exercise or conversion of existing options or other convertible instruments, modestly expanding the company’s quoted share capital and reflecting continued engagement with equity markets.
The application signals incremental dilution for existing shareholders but may also indicate confidence from holders of convertible securities in Bioxyne’s prospects. While the release does not detail use of proceeds or strategic intentions, the additional quoted shares reinforce the company’s active management of its capital structure within ASX listing requirements.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
More about Bioxyne Limited
Bioxyne Limited, listed on the ASX under the code BXN, is a publicly traded company. The announcement relates to its ordinary fully paid shares, indicating ongoing capital market activity, though the specific industry and business operations are not disclosed in the release.
Average Trading Volume: 2,975,031
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$112M
Learn more about BXN stock on TipRanks’ Stock Analysis page.